Depomed Announces Presentation of Cebranopadol Data at World Institute of Pain Congress

| Source: Assertio Therapeutics, Inc. Assertio Therapeutics, Inc.

NEWARK, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that clinical data from two Phase IIb trials as well as human abuse potential and respiratory depression studies conducted by Grünenthal GmbH (“Grünenthal”) will be presented at the 8th World Congress of the World Institute of Pain (WIP) to be held May 20-23, 2016 at the New York Hilton Hotel in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grünenthal.

The following posters will be available for viewing for the duration of the conference beginning Friday May 20th at 5:00pm EDT:

Cebranopadol, A Novel, First-In-Class Analgesic: Efficacy, Safety, Tolerability in Patients with Mixed Chronic Low Back Pain 

Cebranopadol, A Novel, First-In-Class Analgesic: Efficacy, Safety, Tolerability in Patients with Pain Due to Diabetic Peripheral Neuropathy (DPN) 

Cebranopadol: A Novel, First-In-Class Analgesic in Development for Chronic Pain Conditions – Effects on Respiration in Healthy Human Volunteers 

Cebranopadol: A Novel First-In-Class Analgesic in Development for Chronic Pain Conditions – Results from a Human Abuse Potential Study in Non-Dependent Recreational Opioid Users

Top-line data from these trials were presented as part of Depomed’s Investor and Analyst Day in March. The replay of the presentation as well as the corresponding slide deck can be found in the Investors section of Depomed’s website at www.Depomed.com.  

Information about the 8th World Congress of the World Institute of Pain can be found at: http://wip2016.kenes.com/

About Cebranopadol

Cebranopadol is a novel, first-in-class analgesic that acts as a nociceptin/orphanin FQ peptide (NOP) receptor and opioid receptor agonist. These mechanisms, which have been shown to synergize, result in both a comparable efficacy and broader analgesic spectrum versus standard mu-opioid receptor agonists as well as an improved safety profile, particularly as it pertains to respiratory depression. In total, cebranopadol has been studied in approximately 2,000 patients worldwide having completed several Phase II trials in painful diabetic peripheral neuropathy (PDPN), osteoarthritis (OA) and chronic lower back pain (cLBP) and is ready for Phase III development.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.


            











    

        

        
Coordonnées